Abstract
Background: Schizophrenia is a chronic disease with acute psychotic symptoms, which is having frequent recurrence. Paliperidone palmitate (PP) is a second-generation antipsychotic drug to treat schizophrenia.
Aims: The aim of the study was to prepare lyophilized nanoemulsifying drug delivery system (NEDDS) of paliperidone (PD).
Objectives: The primary objective of the current research work was to develop a lyophilized nanoemulsifying drug delivery system (NEDDS) of paliperidone (PD) to improve its oral bioavailability and stability.
Methods: Optimization using D-Optimal Mixture Design DMD) was conducted, and optimized NEDDS was further lyophilized to improve stability. The lyophilized optimized NEDDS was further evaluated for biopharmaceutical evaluation.
Results: A saturation solubility study revealed Peceol, Tween 80, and Plurol Olique CC497 as suitable candidates for oil, surfactant, and co-surfactant, respectively. Optimized NEDDS of PD showed mean globule size (MGS) of 185 nm, PDI of 0.27 and cumulative % drug release within 15 min Q15 of 86.6%. Lyophilized optimized NEDDS was found to have no significant change in quality attributes within the stability study period. A pharmacokinetic study revealed more than two-fold increases in bioavailability for lyophilized optimized NEDDS.
Conclusion: Hence, lyophilized NEDDS of PD can be used as an effective approach for the improvement of oral bioavailability and stability.
Graphical Abstract
[http://dx.doi.org/10.12740/PP/64581] [PMID: 28455891]
[http://dx.doi.org/10.1080/14740338.2017.1288716] [PMID: 28140680]
[http://dx.doi.org/10.1080/01932691.2011.574920]
[http://dx.doi.org/10.1007/s13205-014-0214-0]
[http://dx.doi.org/10.1016/j.ijpharm.2015.11.045] [PMID: 26642946]
[http://dx.doi.org/10.2174/2211738510666220817124744] [PMID: 35980062]
[http://dx.doi.org/10.3109/10717544.2016.1162876] [PMID: 27022886]
[http://dx.doi.org/10.3390/polym13142317] [PMID: 34301073]
[http://dx.doi.org/10.1208/s12249-014-0087-x] [PMID: 24578237]
[http://dx.doi.org/10.1002/9781118895238]
[http://dx.doi.org/10.1016/j.ultsonch.2017.09.042] [PMID: 29137746]
[http://dx.doi.org/10.3390/molecules24112066] [PMID: 31151246]
[http://dx.doi.org/10.1016/j.jddst.2018.06.021]
[http://dx.doi.org/10.1016/j.jddst.2020.101819]
[http://dx.doi.org/10.1016/j.jddst.2021.103047]
[http://dx.doi.org/10.1016/j.jddst.2020.101734]
[http://dx.doi.org/10.3109/10717544.2014.891270] [PMID: 24601856]
[http://dx.doi.org/10.1016/j.molliq.2016.02.081]
[http://dx.doi.org/10.1016/j.jsps.2021.09.016] [PMID: 34819790]
[http://dx.doi.org/10.1016/j.ijpharm.2020.119655] [PMID: 32712252]
[http://dx.doi.org/10.1007/s13346-020-00772-x]
[http://dx.doi.org/10.3390/pharmaceutics12090873] [PMID: 32937773]
[http://dx.doi.org/10.2147/IJN.S287665] [PMID: 33603359]
[http://dx.doi.org/10.1208/s12249-018-0991-6] [PMID: 29637496]
[http://dx.doi.org/10.1016/j.ejps.2017.09.001] [PMID: 28889028]
[http://dx.doi.org/10.1007/s12272-013-0064-z] [PMID: 23446651]
[http://dx.doi.org/10.1080/21691401.2017.1394872]
[http://dx.doi.org/10.1007/s13346-021-01083-5] [PMID: 34671949]
[http://dx.doi.org/10.1016/j.xphs.2018.02.003] [PMID: 29432761]
[http://dx.doi.org/10.1080/03639045.2020.1775632] [PMID: 32486863]
[http://dx.doi.org/10.1007/s13346-021-01042-0] [PMID: 34505271]
[http://dx.doi.org/10.1016/j.colsurfb.2019.110611] [PMID: 31704609]
[http://dx.doi.org/10.1016/j.ijpharm.2020.119180] [PMID: 32135227]
[http://dx.doi.org/10.1016/j.ijpharm.2018.11.036] [PMID: 30448315]
[http://dx.doi.org/10.1016/j.jddst.2020.101783]
[http://dx.doi.org/10.1208/s12249-019-1411-2]
[http://dx.doi.org/10.3390/nano10091657] [PMID: 32846957]
[http://dx.doi.org/10.1208/s12249-008-9178-x] [PMID: 19148761]
[http://dx.doi.org/10.1016/j.ejps.2020.105690] [PMID: 33359617]
[http://dx.doi.org/10.1016/j.jddst.2017.04.004]
[http://dx.doi.org/10.1007/s12247-023-09714-9]